$NXEN (at $0.41) is medical cannabis with a 4.1M Float, 55.4M O/S, and a great management line-up -- SoBe Beverage co-founder, guys who have worked for Pfizer, Johnson & Johnson, Merck, and TEVA.
Plus, they filed their CSE cross-list at the end of August, which means it could be official any day.
Their 10-K talked about their treatment for Myotonic Dystrophy and Myotonia, which has a world-renowned expert as the advisor, may get FDA Orphan Drug status. They just had news about this treatment earlier in the week as well.
Lots of great things on the horizon, but the stock has just started to get going after it's R/M, then R/S, and now shares being released from a long restriction. Literally buying at the "ground level".
Some extra DD on the management at www.OwnTheFloat.com, but company website is NexienBiopharma.com with good info.
